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prostate volume and volume that received 100% of the prescribed iso-
dose, respectively) achieved in glands ≥ 60 cc were not significantly 
different compared to those with glands < 60 cc (p≥ 0.2). Nonetheless, 
biochemical control of disease in patients with larger CTV was 
significantly higher (91% vs 78% at 6 years; p = 0.004). In uni and 
multivariate analysis, CTV was a significant predictor for risk of 
biochemical relapse. This was not at the expense of an increase in 
either moderate (p = 0.6) or severe (p = 0.3) late genitourinary 
toxicity. Usage of hormonal therapy was 17% lower in the large gland 
group (p = 0.01). There was no significant difference in FFbR or in the 
incidence of late genitourinary or rectal morbidity between the three 
fractionation schedules. 
 
  
Conclusions: Prostate gland size does not affect dosimetric 
parameters in HDR-BT assessed by D90 and V100. In patients with 
larger prostate glands a significantly higher biochemical control of 
disease has been observed with no difference in late toxicity. This 
improvement cannot be attributed to differences in dosimetry. Gland 
size should not be considered when selecting patients for HDR-BT.  
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Purpose/Objective: Even though calcifications are observed in clinical 
practice, the actual dose calculation algorithm (TG-43) overrides 
them with water material and density. However, it is a known fact 
that at low energy in LDR seed implants the cross section depends 
strongly on the effective atomic number, increasing the probability of 
important dose discrepancies around the calcified regions. It is 
hypothesized that significant effects on the dose metrics such as the 
dose volume histogram (DVH), target volume and urethra are not 
taken into accounts. This study investigates these effects on delivered 
dose from calcifications in post-implant dosimetry.  
Materials and Methods: 42 patients with visible calcifications in the 
prostate were identified. Threshold segmentation is used to 
distinguish normal prostate tissue from calcification. Monte Carlo (MC) 
simulations are made with the Geant4-based ALGEBRA software [1] in 
1mm3 voxels. Materials are assigned based on TG-186 recom-
mendations and the sources are explicitly modeled. Breast 
calcification definition is used to define the prostate calcification with 
density taken from the CT numbers. We identified 6 different dose 
calculation scenarios for our study: MC in water with (1) and without 
(2) seeds, 2) MC in a water prostate with densities from the CT but 
with calcification areas with (3) and without seeds (4) and finally full 
tissue heterogeneities with (5) and without seeds (6).  
Results: Relative to the TG-43 algorithm, we measure large 
differences, up to -27 (-28)% on the D90 (V100) with full tissue 
heterogeneities and seeds modeled, and up to -25 (-22)% when only 
the calcificified areas and seeds are taken into account. The negative 
sign indicated a decrease in dose relative to TG-43. Calcifications, 
inter-seed attenuation and tissue heterogeneities can lead to 
interplay phenomena. Hot-spot regions as defined by V200 are the 
most affected, with difference to TG-43 up to -74%. The urethra also 
shows significant dose discrepancies depending on the location of the 
calcifications. Urethra D90 differences of -17% relative to full MC 
calculations are observed, -10% considering calcification only. For all 
cases under investigation, the average decrease of D90 is -15% for the 
prostate and -8% for the urethra.  
Conclusions: Taking into account tissue heterogeneities, composition, 
and calcifications composition produces the highest change relative to 
TG-43. Based on the patient cohort, calcifications have a measurable 
impact on the target volume dose parameters and also may bring a 
significant decrease in the delivered dose to the urethra. The real 
composition of the prostate calcification remains to be determined to 
establish a better understanding ofthe dosimetric consequences. 
[1] Afsharpour, et al, 'ALGEBRA: ALgorithm for the Heterogeneous 
Dosimetry Based on GEANT4 for BRAchytherapy.' Physics in Medicine 
andBiology 57, no. 11 (June 7, 2012): 3273–3280.doi:10.1088/0031-
9155/57/11/3273. 
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Purpose/Objective: MRI provides the gold standard for tumour 
delineation in gynaecological brachytherapy. While traditionally CT 
has been used for applicator reconstruction and then fused with MRI, 
in recent years the use of MRI only for the reconstruction of 
applicators, with or without MRI compatible line markers, has become 
more widespread. The purpose of this study is to evaluate the inter-
operator differences in DVH parameters for OAR and HR-CTV when 
reconstructing titanium applicators with a fixed geometry, based only 
on T2 MRI images. Line markers are not currently commercially 
available for this applicator type. GEC-ESTRO recommendations 
regarding HR-CTV were followed and identical library plans used, 
prescribing to point A. 
Materials and Methods: Three patient plans using an identical OAR 
and HR-CTV structure set were used to retrospectively reconstruct a 
titanium Rotterdam type applicator using a 3D library model. Eight 
regular planners (radiographers, medical physicists and dosimetrists) 
independently reconstructed applicators and set an origin point based 
upon the applicator model. Identical library plans were loaded onto 
each applicator and the variations in DVH parameters for both HR-CTV 
and OAR assessed. 
Results: Co-ordinate positions of point A were used as a surrogate for 
applicator model alignment to the applicator image. Vector 
differences between eight regular planners were assessed by 
comparing the average co-ordinates of point A between all of the 
plans. The vector differences between the co-ordinates, compared 
against the average co-ordinates, show that the mean absolute 
difference between planners is 1.0mm (SD 0.4mm). All values were 
within 2mm, which shows good agreement between planners.  
The average percentage absolute-differences in DVH parameters 
arising from these variations, when compared against the average 
value for each, can be seen in Table 1. 
 
Table 1 
These results show that the average absolute differences are very low 
(<=3.3%), with the highest difference being for the HR-CTV D100%, 
which is known to be less reproducible than the D98% for HR-CTV.  
 
  
